New angiotensin II-receptor agonist, useful for treating neurodegenerative diseases, preferably Alzheimer's dementia, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent introduces new angiotensin II-receptor agonists, which are compounds designed to activate angiotensin II receptors in the body. These compounds demonstrate neuroprotective and brain-enhancing (nootropic) properties, and are particularly aimed at treating neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Alzheimer's disease to slow cognitive decline or progression.
• Therapy for Parkinson's disease to alleviate symptoms or slow disease progression.
• Management of Huntington's disease to reduce neurodegeneration.
• Therapeutic intervention for amyotrophic lateral sclerosis (ALS) to protect nerve cells and slow disease advancement.
• Potential use as a brain-enhancing drug (nootropic) to improve learning, memory, or cognitive functions.
• Possible application as an anticonvulsant for seizure disorders.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new mechanism of action (angiotensin II-receptor agonism) for neuroprotection, differing from current therapies.
• Targets multiple neurodegenerative diseases with a single class of compounds.
• Potential to slow progression of debilitating neurological conditions and improve patients' quality of life.
• Could offer fewer side effects and improved tolerability compared to existing medications.
• May enhance cognitive function and offer protection against further neuronal loss.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Angiotensin II-receptor agonist is new. An independent claim is included for a component comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, Novokinin (Arg-Pro-Leu-Lys-Pro-Trp), propylthienyl derivative, N-butylcarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5 isobutylthiophene-2-sulfonamide, N-(N-butyl-methylaminocarbonyl)-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, 2-isobutylthiophene, N-tert-butyl-5-isobutylthiophene-2-carboxamide, 3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-N-tert-butylthiophene-2-carboxamide, 3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-carboxamide, N-butylsulfonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-carboxamide, 3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-carbonitrile, 5-(3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-yl)-1H-tetrazole, N-tert-butyl-5-propylthiophene-2-sulfonamide, N-tert-butyl-4-butyloxybenzenesulfonamide, N-tert-butyl-3-(4-imidazol-1-ylmethylphenyl)-5-propylthiophene-2-sulfonamide, N-tert-butyl-2-(4-imidazol-1-ylmethylphenyl)-4-butyloxybenzenesulfonamide, N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-propylthiophene-2-sulfonamide, or N-butyloxycarbonyl-2-(4-imidazol-1-ylmethylphenyl)-4-butyloxybenzenesulfonamide, N-butyloxycarbonyl-3-(4-(2-oxo-pyrrolidin-1-yl-methyl)phenyl)-5-isobutylthiophene-2-sulfonamide. ACTIVITY : Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant. MECHANISM OF ACTION : Angiotensin II-receptor agonist.